



An Analysis of a Polypharmacy Deprescribing Program for Anticholinergics and Concurrent Opioid and Benzodiazepine Usage for Medicare Beneficiaries

Scott Weber, PharmD; Agata Siwak, PharmD, MSBA; Alex J. Stuhl, MSBA;
Courtney Kapitz, PharmD; Mandy Deschaine, MS; Marnie Wickizer, PharmD, MBA, CDCES



BACKGROUND

- Polypharmacy of anticholinergic and high-risk drug classes, such as opioids and benzodiazepines, are contributing factors for medication-related complications in older adults. Thus, appropriate deprescribing of these medications is warranted to reduce a variety of health risks in senior populations such as falls and worsening cognition.¹
- The Centers for Medicare and Medicaid Services (CMS) has added two new Star Ratings measures: Concurrent Use of Opioids and Benzodiazepines (COB) and Polypharmacy Use of Multiple Anticholinergic Medications in Older Adults (POLY-ACH).² Performance on these new measures highlights the importance of early detection and safety for Medicare populations.
- It is unclear how current deprescribing campaigns will impact CMS Star Ratings.

OBJECTIVE

- To design and implement a proactive, data-informed strategy for identifying and removing members at risk of inclusion in COB and POLY-ACH cohorts with the intention that removal from COB and POLY-ACH cohorts will improve Star Ratings.


METHODS

DATA SOURCE

- Navitus prescription claims database

DESIGN

- Paired pharmacy claims data were analyzed from a 4-month pre and post period following a pilot deprescribing intervention in December 2024 and February 2025. The intervention consisted of a deprescribing-focused letter mailed to prescribers with identified patient medication profiles.



STUDY POPULATION

- Members were included in the sample if age ≥ 65; use of ≥ 2 measure included medications, and overlapping claims ≥ 50% in the pre and post period which means a total of ≥ 60 cumulative days of overlap.

OUTCOMES

- The primary outcome was the number of members who were below the 50% overlap threshold.
- The secondary exploratory outcomes were improvement in average drug burden index (DBI)³⁻⁴ anticholinergic burden index (ACB)⁵⁻⁶, and average number of claims per member. ACB will not be applicable to COB based upon pharmacologic action of COB medications.

STATISTICAL ANALYSIS

- Primary and secondary outcomes were analyzed with descriptive statistics and Wilcoxon Signed Rank post-hoc testing with Bonferroni corrected p-values.
- Successful beneficiaries in the December group were removed from the statistical analysis of the February group.

RESULTS

After the first mailing, the improvement in overlap percentage < 50% was as follows:

POLY-ACH, 49.5% of members improved • COB, 30.3% of members improved

TABLE 1. BASELINE CHARACTERISTICS OF THE POLY-ACH AND COB COHORTS

Baseline Characteristics	POLY-ACH (n=100)	COB (n=99)
Age, mean [SD]	73.3 [6.1]	72.3 [7.7]
Male, %	24%	32%
Female, %	76%	68%
Baseline Primary Outcome		
Overlap %, mean [SD]	67.7 [12.4]	70.7 [12.7]
Baseline Secondary Outcomes		
DBI, mean [SD]	0.70 [0.1]	0.80 [0.08]
# Claims, mean [SD]	5.3 [3.3]	8.7 [2.4]
ACB, mean [SD]	15.3 [9.1]	N/A

*DBI=drug burden index, ACB=anticholinergic burden index

FIGURE 4. POLY-ACH, ACB

The average total sum of ACB per member in the Pre-Intervention group was 15.3 [9.1] for the December group and 25.9 [12.7] for the February group. A reduction in the average total sum of ACB per member was observed in the December group (12.5 [8.5]; P < 0.001) but this trend was not observed in the February group (22.5 [13.5]; P = 0.21).




FIGURE 2. COB, DBI

The average DBI in the Pre-Intervention group was 0.80 [0.08] in December and February. There was no change between the Pre-Intervention and December groups, and a decrease for the February group (0.79 [0.08]; P < 0.001).




FIGURE 5. POLY-ACH, DBI

The average DBI in the Pre-Intervention group was 0.70 [0.1] in December and February. Both the December and February groups had an average DBI smaller than the Pre-Intervention group (0.66 [0.1]; P = 0.07 and 0.67 [0.1]; P = 0.12, respectively).




FIGURE 3. COB, CLAIMS

The average number of total claims per member in the Pre-Intervention group was 8.7 [2.4] for the December group, and 9.2 [2.4] for the February group. There was a reduction in the average number of total claims per member in the December group (8.2 [2.7]; P = 0.01) and in the February group (8.5 [2.5]; P = 0.015).





FIGURE 6. POLY-ACH, CLAIMS

The average number of total claims per member in the Pre-Intervention group was 5.3 [3.3] for the December group, and 9.0 [4.9] for the February group. A reduction in the average number of total claims was observed in the December group (4.3 [3]; P < 0.001) but this trend was not observed in the February group (8.1 [4.8]; P = 0.33).



SUMMARY OF RESULTS

Overall, the pilot program helped decrease the number of overlapping claims that would be included in POLY-ACH and COB Star Measures.

CONCLUSIONS

- This pilot program identified members at high risk for inclusion in CMS Star Ratings measures for POLY-ACH and COB, while effectively and significantly removing them from their respective cohorts.
- Integrating this approach into clinical workflows supports early intervention, enhances patient safety through a reduction in medication-related complications, and will improve performance on Star Ratings measures.
- Multiple interventions are needed for POLY-ACH and COB deprescribing due to the challenges faced by both patients and prescribers for tapering, discontinuing, and/or substituting safer and effective agents.

LIMITATIONS

- Interventions were focused on Medicare populations limiting generalizability.
- No causal relationship can be concluded from this study.
- The study was based upon pharmacy claims, not medical claims.

DISCLOSURE

This research was conducted by Navitus Health Solutions, based in Madison, WI, without external funding.

REFERENCES

1. Pereira F, Wernli B, von Gunten A, Carral MDR, Martins MM, Verloo H. Functional status among poly medicated geriatric inpatients at discharge: a population-based hospital register analysis. *Geriatrics*. 2021;6(3):86. doi:10.3390/geriatrics6030086
2. Centers for Medicare & Medicaid Services. Medicare program; changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Program for contract year 2024 – remaining provisions and contract year 2025 policy and technical changes to the Medicare Advantage Program, Medicare Prescription Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (PACE): final rule. *Federal Register*. 2024;89(79):30448-30848
3. Blalock SJ, Renfro CP, Robinson JM, Farley JF, Busby-Whitehead J, Ferreri SP. Using the drug burden index to identify older adults at highest risk for medication-related falls. *BMC Geriatrics*. 2020;20(1):208. doi:10.1186/s12877-020-01598-5
4. Masnoon N, Lo S, Hilmer S. A stewardship program to facilitate anticholinergic and sedative medication deprescribing using the drug burden index in electronic medical records. *Br J Clin Pharmacol*. 2023;89(2):687-698. doi:10.1111/bcp.15517
5. McAnena AP, Zullo AR, Joshi R, Daiello LA, Berry SD. High anticholinergic burden of patients hospitalized for hip fracture reveals a target for deprescribing. *JAMDA*. 2025;26(5):105537. doi:10.1016/j.jamda.2025.105537
6. Reinold J, Braitmaier M, Riedel O, Haug U. Anticholinergic burden: first comprehensive analysis using claims data shows large variation by age and sex. *PLoS One*. 2021;16(6):e0253336. doi:10.1371/journal.pone.0253336